MRI-based estimation of liver function: Gd-EOB-DTPA-enhanced T1 relaxometry of 3T vs. The MELD score

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Haimerl, Michael ^a   Verloh, Niklas ^a   Fellner, Claudia ^a   Zeman, Florian ^a   Teufel, Andreas ^a   Fichtner Feigl, Stefan ^a   Schreyer, Andreas G ^a   Stroszczynski, Christian ^a   Wiggermann, Philipp ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM PENTETATE; GADOXETIC ACID;

BIOLOGICAL MODEL; COMPUTER ASSISTED DIAGNOSIS; COMPUTER SIMULATION; DIAGNOSTIC USE; FEMALE; HUMAN; LIVER DISEASES; LIVER FUNCTION TEST; MALE; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY;

COMPUTER SIMULATION; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER DISEASES; LIVER FUNCTION TESTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84903977717     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05621     Document Type: Article

References (44)

1. Hammerstingl, R. et al. Diagnostic efficacy of gadoxetic acid (Primovist)- enhanced MRI and spiral CT for a therapeutic strategy: comparison with intraoperative and histopathologic findings in focal liver lesions. Eur Radiol 18, 457-467 (2008). (Pubitemid 351248177)
2. Hamm, B. et al. Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging. Radiology 195, 785-792 (1995).
3. Leonhardt, M. et al. Hepatic uptake of the magnetic resonance imaging contrast agent Gd-EOB-DTPA: role of human organic anion transporters. Drug Metab Dispos 38, 1024-1028 (2010).
4. Ahn, S. S. et al. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 255, 459-466 (2010).
5. Ryeom, H. K. et al. Quantitative evaluation of liver function with MRI Using Gd- EOB-DTPA. Korean J Radiol 5, 231-239 (2004).
6. Kim, T. et al. Experimental hepatic dysfunction: evaluation by MRI with Gd-EOBDTPA. J Magn Reson Imaging 7, 683-688 (1997). (Pubitemid 28365618)
7. Tsuda, N., Harada, K. & Matsui, O. Effect of change in transporter expression on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging during hepatocarcinogenesis in rats. J Gastroenterol Hepatol 26, 568-576 (2011).
8. Tamada, T. et al. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur J Radiol 80, e311-316 (2011).
9. Verloh, N. et al. Impact of liver cirrhosis on liver enhancement at Gd-EOB-DTPA enhanced MRI at 3 Tesla. Eur J Radiol 82, 1710-1715 (2013).
10. Higaki, A. et al. Potential clinical factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhanced MR imaging. Magn Reson Imaging (2012).
11. Motosugi, U. et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging 30, 1042-1046 (2009).
12. Kubota, K. et al. Correlation of liver parenchymal gadolinium- ethoxybenzyl diethylenetriaminepentaacetic acid enhancement and liver function in humans with hepatocellular carcinoma. Oncol Lett 3, 990-994 (2012).
13. Tajima, T. et al. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J Comput Assist Tomogr 34, 362-366 (2010).
14. Seale, M. K., Catalano, O. A., Saini, S., Hahn, P. F. & Sahani, D. V. Hepatobiliaryspecific MR contrast agents: role in imaging the liver and biliary tree. Radiographics 29, 1725-1748 (2009).
15. Tsuda, N., Okada, M. & Murakami, T. Potential of gadolinium- ethoxybenzyldiethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest Radiol 42, 242-247 (2007). (Pubitemid 46398863)
16. Shimizu, J. et al. Evaluation of regional liver function by gadolinium-EOB-DTPAenhanced MR imaging. Dig Dis Sci 44, 1330-1337 (1999). (Pubitemid 29404293)
17. Haimerl, M. et al. Assessment of clinical signs of liver cirrhosis using T1 mapping on Gd-EOB-DTPA-enhanced 3T MRI. PLoS One 8, e85658 (2013).
18. Yamada, A. et al. Quantitative evaluation of liver function with use of gadoxetate disodium-enhanced MR imaging. Radiology 260, 727-733 (2011).
19. Katsube, T. et al. Estimation of liver function using T1 mapping on Gd-EOBDTPA- enhanced magnetic resonance imaging. Invest Radiol 46, 277-283 (2011).
20. Kim, W. R. et al. Hyponatremia and mortality among patients on the livertransplant waiting list. N Engl J Med 359, 1018-1026 (2008).
21. Kamath, P. S. & Kim, W. R. The model for end-stage liver disease (MELD). Hepatology 45, 797-805 (2007). (Pubitemid 46450631)
22. Wiesner, R., Lake, J. R., Freeman, R. B. & Gish, R. G. Model for end-stage liver disease (MELD) exception guidelines. Liver Transpl 12, S85-87 (2006). (Pubitemid 44911776)
23. Kremers, W. K. et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 39, 764-769 (2004). (Pubitemid 38337656)
24. Botta, F. et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut 52, 134-139 (2003). (Pubitemid 36020780)
25. Tamada, T. et al.Gd-EOB-DTPA enhancedMRimaging: evaluation of biliary and renal excretion in normal and cirrhotic livers. Eur J Radiol 80, e207-211 (2011).
26. Tschirch, F. T. et al. Contrast-enhanced MR cholangiography with Gd-EOBDTPA in patients with liver cirrhosis: visualization of the biliary ducts in comparison with patients with normal liver parenchyma. Eur Radiol 18, 1577-1586 (2008).
27. Wibmer, A. et al. Liver transplantation: impaired biliary excretion of gadoxate is associated with an inferior 1-year retransplantation-free survival. Invest Radiol 47, 353-358 (2012).
28. Watanabe, H. et al. Staging hepatic fibrosis: comparison of gadoxetate disodiumenhanced and diffusion-weighted MR imaging - preliminary observations. Radiology 259, 142-150 (2011).
29. Motosugi, U. et al. Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging 29, 1047-1052 (2011).
30. Verloh, N. et al. Assessing liver function by liver enhancement during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MRI at 3 Tesla. Eur Radiol (2014).
31. Materne, R. et al. Assessment of hepatic perfusion parameters with dynamic MRI. Magn Reson Med 47, 135-142 (2002). (Pubitemid 34019702)
32. Wiesner, R. et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124, 91-96 (2003). (Pubitemid 36055342)
33. Thomsen, C., Christoffersen, P.,Henriksen,O. & Juhl, E. Prolonged T1 in patients with liver cirrhosis: an in vivo MRI study. Magn Reson Imaging 8, 599-604 (1990). (Pubitemid 20321976)
34. Heye, T. et al. MR relaxometry of the liver: significant elevation of T1 relaxation time in patients with liver cirrhosis. Eur Radiol 22, 1224-1232 (2012).
35. Mathur-De Vre, R. Biomedical implications of the relaxation behaviour of water related to NMR imaging. Br J Radiol 57, 955-976 (1984). (Pubitemid 15213087)
36. Wynn, T.A. Cellular and molecular mechanisms of fibrosis. J Pathol 214, 199-210 (2008). (Pubitemid 351160157)
37. Goldberg, H. I. et al. Hepatic cirrhosis: magnetic resonance imaging. Radiology 153, 737-739 (1984). (Pubitemid 15190051)
38. Kreft, B. et al. Evaluation of different models of experimentally induced liver cirrhosis for MRI research with correlation to histopathologic findings. Invest Radiol 34, 360-366 (1999). (Pubitemid 29198346)
39. Kim, K. A. et al.Quantitative evaluation of liver cirrhosis using T1 relaxation time with 3 tesla MRI before and after oxygen inhalation. J Magn Reson Imaging 36, 405-410 (2012).
40. Wibmer, A. et al. Liver failure after major liver resection: risk assessment by using preoperative Gadoxetic acid-enhanced 3-T MR imaging. Radiology 269, 777-786 (2013).
41. de Bazelaire, C. M., Duhamel, G. D., Rofsky, N. M. & Alsop, D. C. MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. Radiology 230, 652-659 (2004). (Pubitemid 38252858)
42. Vogl, T. J. et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 200, 59-67 (1996). (Pubitemid 26197732)
43. Frericks, B. B. et al. Qualitative and quantitative evaluation of hepatocellular carcinoma and cirrhotic liver enhancement using Gd-EOB-DTPA. AJR Am J Roentgenol 193, 1053-1060 (2009).
44. Reimer, P., Schneider, G.&Schima, W. Hepatobiliary contrast agents for contrastenhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 14, 559-578 (2004). (Pubitemid 38444568)